Brussels, 1 - 2 March 2018
• Update on EU legislation and case law
• Incentives on innovation
• Access to data and data disclosure
Click here for more information and a detailed programme [1]
Objective
This annual conference will bring legal practitioners working with the pharmaceutical sector up-to-date on the latest relevant regulatory developments, legislative initiatives and case law.
Key Topics
Competition law in the pharmaceutical sector
Patent law in the pharmaceutical sector and other intellectual property incentives on innovation
EU pharmaceutical law round-up
Who should attend?
In-house counsel and legal or patent advisers in pharmaceutical companies; lawyers in private practice dealing with pharmaceuticals and medical devices; lawyers in national ministries and authorities dealing with regulation of the sector.
Register until the 1 February and save 10% [1]
Speakers
Simone Boselli, Public Affairs Director, EURORDIS, Brussels
Nicola Dagg, Partner, Allen & Overy, London
Juergen Dressel, Head, Global Patent Litigation Strategy, Novartis Pharma AG, Basel
Brian Kelly, Partner, Covington & Burling, London
John Lisman, Lisman Legal Life Sciences B.V., Heijen
Catherine Longeval, Partner, Van Bael & Bellis, Brussels
Geneviève Michaux, Partner, Mayer Brown, Brussels
Alexander Natz, Secretary General, EUCOPE, Brussels
Rositsa Pencheva, Case Handler, DG Competition, European Commission, Brussels
Peter Picht, Chair of Business and Commercial Law, Centre for Intellectual Property and Competition Law, University of Zurich
Tapani Piha, Head of Unit, Cross-Border Healthcare and eHealth, DG Health & Food Safety, European Commission, Brussels
Aleksandar Rusanov, Legal Administrator, European Medicines Agency, London
Bart Van Vooren, Associate, Covington & Burling, Brussels
www.era.int [2]
Links:
[1] https://www.era.int/cgi-bin/cms?_SID=e43ddc268140db54f3ba7214787f9e45b99da6b800576258191385&_sprache=en&_bereich=artikel&_aktion=detail&idartikel=127277
[2] https://www.era.int/